CD19 in acute lymphoblastic leukaemia
6 EU-approved indications in acute lymphoblastic leukaemia need a CD19 result: blinatumomab (2nd line), blinatumomab (3rd line+), blinatumomab (1st line), blinatumomab (2nd line), blinatumomab (consolidation) and blinatumomab (consolidation).
Lineage
Line of therapy
| Drug | Biomarker requirement | Regimen | Setting | Conditions |
|---|---|---|---|---|
| CD19-positive6 | ||||
Blincyto | Philadelphia chromosome-negative | Monotherapy | 1L | B-cell precursor ALL only; In first or second complete remission with minimal residual disease (MRD) ≥ 0.1% |
Blincyto | Philadelphia chromosome-negative | Monotherapy | Consol. | B-cell precursor ALL only; Children and adolescents only; Aged 1 month or older; high-risk |
Blincyto | Philadelphia chromosome-negative | Monotherapy | Consol. | B-cell precursor ALL only |
Blincyto | Philadelphia chromosome-negative | Monotherapy | 2L | B-cell precursor ALL only |
Blincyto | Philadelphia chromosome-negative | Monotherapy | 2L | B-cell precursor ALL only; Children and adolescents only; After at least two prior therapies, or prior allogeneic haematopoietic stem cell transplantation; Aged 1 month or older |
Blincyto | Philadelphia chromosome-positive | Monotherapy | 3L+ | B-cell precursor ALL only; Failed treatment with at least 2 tyrosine kinase inhibitors (TKIs); No alternative treatment options |
3 approvals for ALL need no biomarker and apply whatever the result. All approvals for ALL
See also
Label wording6
The sentence from section 4.1 of the SmPC that each indication above comes from.
- Blinatumomab (Blincyto)
BLINCYTO is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL).
- Blinatumomab (Blincyto)
BLINCYTO is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome-positive B-cell precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options.
- Blinatumomab (Blincyto)
BLINCYTO is indicated as monotherapy for the treatment of adults with Philadelphia chromosome-negative CD19 positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.
- Blinatumomab (Blincyto)
BLINCYTO is indicated as monotherapy for the treatment of paediatric patients aged 1 month or older with Philadelphia chromosome-negative CD19 positive B-cell precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation.
- Blinatumomab (Blincyto)
BLINCYTO is indicated as monotherapy for the treatment of paediatric patients aged 1 month or older with high-risk first relapsed Philadelphia chromosome-negative CD19 positive B-cell precursor ALL as part of the consolidation therapy (see section 4.2).
- Blinatumomab (Blincyto)
BLINCYTO is indicated as monotherapy as part of consolidation therapy for the treatment of adult patients with newly diagnosed Philadelphia chromosome negative CD19 positive B-cell precursor ALL.